Core Insights - ALX Resources Corp. has completed reconnaissance prospecting and sampling programs at its 100%-owned Cannon Copper Project, located in Ontario, Canada, which includes the historic Cannon Copper Mine site [2][3]. Group 1: Prospecting and Sampling Programs - The 2024 prospecting and sampling programs were conducted in two phases during June and August, focusing on collecting mineralized rock samples and applying modern geochemical analysis [3][10]. - A total of 22 rock samples were collected, with a notable grab sample returning 1.44% copper, while results from the August samples are still pending [3][10]. - The programs also involved locating historical drill holes, with 9 successfully identified, and conducting a Soil Gas Hydrocarbon (SGH) sampling survey, which collected 176 samples [3][11]. Group 2: Geophysical Studies - The 2024 studies included Acquired Inductively Induced Polarization (AIIP) and Structural Complexity (SC) analyses, which identified a broad exploration target area around the known mineralized trend [5][6]. - The AIIP processing algorithm applied to 2021 VTEM data revealed subtle effects correlating with low resistivities, particularly in the central region of the project [6][9]. - The SC study outlined a structurally complex target area of approximately 2.9 square kilometers, which is crucial for identifying potential mineral deposits [7][9]. Group 3: Historical Context and Future Plans - The Cannon Copper Project is located in a historically rich copper mining district, with past production from 1966 to 1972, and a historical mineral resource estimate of 415,000 tonnes grading 1.8% copper [14]. - The company believes that the historical mine workings may indicate a larger, unexplored mineralizing system, with plans to identify drill targets and apply for an exploration permit [13][14].

Markets soared today on news that the Federal Reserve believes now is the time to start cutting interest rates after several years of high inflation.With the possibility of multiple rate cuts back on the table this year, Real Estate Investment Trusts (REITs) may stand to benefit the most as these equities rely on debt to finance their operations and acquire properties.Seeing as rate cuts would help to stabilize their operating environment here are three REITs to consider that all sport a Zacks Rank #1 (Stro ...

Alexander's (ALX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a changing ...

Here are three stocks with buy rank and strong income characteristics for investors to consider today, August 9th:NexPoint Real Estate Finance (NREF) : This real estate investment trust which originate, structure and invest in first mortgage loans, mezzanine loans, preferred equity and alternative structured financings in commercial real estate properties, as well as multifamily commercial mortgage-backed securities, has witnessed the Zacks Consensus Estimate for its current year earnings increasing 7.8% ov ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark one) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 001-06064 ALEXANDERS INC (Exact name of registrant as specified in its charter) Delaware 51-0100517 | --- | --- | --- | |--------- ...

Evorpacept is the first CD47 blocker to show durable clinical benefit and a well-tolerated safety profile in a prospective randomized trial Evorpacept combination achieved a confirmed overall response rate (ORR) of 40.3% compared to 26.6% for the control arm and demonstrated a median duration of response of 15.7 months compared to 7.6 months in the full trial populationIn the pre-specified population of patients with fresh HER2-positive biopsies, evorpacept combination showed the greatest benefit with ORR o ...

PARAMUS, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- Alexander’s, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable on August 30, 2024 to stockholders of record on August 12, 2024. Alexander’s, Inc. is a real estate investment trust that has five properties in the New York City metropolitan area. CONTACT:GARY HANSEN(201) 587-8541 Certain statements contained herein constitute forward-looking statements as such term is defined in Sec ...

Conference Call and Webcast Today at 4:30 PM EDT SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, announced that the Company will host an investor conference call and webcast today at 4:30 PM EDT to share topline data results from the Phase 2 ASPEN-06 clinical trial evaluating evorpacept for the treatment of advanced HER2- ...

PARAMUS, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE:ALX) today announced that it will file its quarterly report on Form 10-Q for the quarter ended June 30, 2024 with the U.S. Securities and Exchange Commission and issue its second quarter earnings release on Monday, August 5, 2024, before the New York Stock Exchange opens. Vornado Realty Trust (NYSE:VNO), the manager which conducts Alexander's operations, announced it will host its quarterly earnings conference call and an audio webcast ...

Core Viewpoint - Office REITs have shown modest gains in 2023, with an average return of 5.23%, significantly lower than the S&P 500's 18.55% and Nasdaq 100's 21.20% [2][3] Performance Summary - Year-to-date performance of various REIT sectors shows Cannabis at 13.33%, Healthcare at 11.68%, and Office at 5.23%, while the Equity REIT Index averages only 1.07% [3] - The WFH trend has led to a permanent decrease in demand for commercial office space, contributing to increased defaults in commercial real estate loans, particularly office-related loans [4] Company Overview - Alexanders, Inc. (ALX) is a small-cap REIT with a market cap of $1.14 billion, primarily focused on office and retail properties in New York City [4] - ALX has a portfolio of 2.455 million square feet with a 92.5% occupancy rate for office and retail spaces and 96.8% for residential properties as of March 31 [4] Financial Performance - ALX reported Q1 2024 rental revenue of $61.4 million, a 16.1% increase from Q1 2023, while net income rose by 43.8% to $16.1 million [10] - The company experienced a significant drop in cash from financing, down 99.6% year-over-year, due to unusual treasury sales in the previous year [10] Growth Metrics - ALX's FFO (Funds From Operations) has shown a declining trend over the past four years, with a CAGR of -5.03% [12] - The stock price has decreased by 41.27% over the past decade, indicating a bearish long-term trend despite short-term gains [9] Balance Sheet Metrics - ALX has a liquidity ratio of 1.20 and a debt ratio of 50%, with total debts of $1.093 billion against cash and cash equivalents of $536 million [14] - The company has a high Debt/EBITDA ratio of 10.0, indicating significant leverage [14] Dividend Metrics - ALX maintains a quarterly dividend of $4.50, with a payout ratio of 114%, which is considered unsustainable [16] - The company has not cut its dividend during the pandemic, but the current payout ratio raises concerns about future sustainability [16] Valuation Metrics - ALX is currently priced 9.6% above its estimated NAV, with a dividend score of 8.01 and a price/FFO ratio of 17.5 [17] Investor Sentiment - Analysts have mixed ratings on ALX, with one analyst maintaining a Sell rating and a price target of $145, implying a potential downside of 34.5% [19]